Clinical trials: Behavior Disorders in Children
HIV Infections
Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries
The purpose of this study was to examine, in an integrated and comprehensive fashion, three critical questions currently facing HIV-infected pregnant and postpartum women and their infants: 1.
- Trial name
- PROMISE (NCT01061151)
- Testing
- Zidovudine (ZDV), Nevirapine (NVP): Antepartum Mothers, Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail
- Where
- 14 sites in India, Malawi and 5 more
- Volunteers
- 3,747 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Caregivers, Parents
Self-Management in Parents of Technology-Dependent Children
Parent caregivers of children with chronic conditions who require life-saving technology such as mechanical ventilation or feeding tubes must maintain a high level of vigilance 24 hours a day, 7 days a week.
- Conditions
- Caregivers, Parents, Self-Management, Chronic Illnesses, Multiple
- Trial name
- NCT04105244
- Testing
- Resourcefulness Training©
- Where
- United States
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Neurofibromatosis 1
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
Children with neurofibromatosis type 1 (NF1) commonly suffer from the effects of cognitive, behavioral, and motor impairments. At present, there is no specific treatment for this NF1 complication.
- Trial name
- DoDNAC (NCT04481048)
- Testing
- N-Acetyl cysteine
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Neurofibromatosis 1
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1
Children with neurofibromatosis type 1 (NF1) commonly suffer from the effects of cognitive, behavioral, and motor impairments. At present there is no specific treatment for this NF1 complication.
- Trial name
- NF1NAC (NCT04481035)
- Testing
- N-acetylcysteine (NAC)
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Obesity, Adolescent, Adolescent Behavior
Study of Nutrition and Activity in Kids
While a substantial body of research suggests that RRV is related to obesity, there is very little research on factors that contribute to the RRV of food, particularly how patterns of eating can increase or decrease the…
- Trial name
- SNAK (NCT04027608)
- Testing
- Reinforcing value of HED and LED foods in response to snack food monotony
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Alzheimer Disease, Dementia
Technology and Family Thriving Study
The purpose of this project is to test the impact of different forms of technology (virtual reality vs. video chat) on quality of life and family relationships in older adults who reside in senior living communities and an adult…
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burnout, Quality of Life
- Trial name
- Thrive (NCT05150990)
- Testing
- Virtual Reality, Video Chat
- Where
- 27 sites in United States
- Volunteers
- 186 people
- Sponsor
- University of California, Santa Barbara
Obsessive-Compulsive Disorder
Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder
This study measures the occurrence of certain side effects linked to antidepressant use and evaluates the effectiveness of the medication sertraline plus cognitive behavioral therapy to treat people with obsessive-compulsive…
- Trial name
- NCT00382291
- Testing
- Regular Titration, Slow Titration
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- University of Florida
Attention-Deficit/Hyperactivity Disorder (ADHD)
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- ADHD (NCT04786990)
- Testing
- SPN-812
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 96 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder Symptoms
Implementation Strategy Resource Package for Behavioral Classroom Interventions: Pilot Test
The purpose of this study is to pilot test for feasibility and initial promise an implementation strategy resource package that aims to support teachers in using behavioral classroom management interventions for children with…
- Trial name
- NCT05489081
- Testing
- Positive Behavior Management Toolkit
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Attention-Deficit Hyperactivity Disorder (ADHD)
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
A study to evaluate the efficacy and safety of dasotraline in children 6 to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.
- Trial name
- NCT03231800
- Testing
- dasotraline
- Where
- 8 sites in United States
- Volunteers
- 95 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Hyperactivity Disorder
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B).
- Trial name
- NCT04085172
- Testing
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
- Where
- 50 sites in United States, Austria and 7 more
- Volunteers
- 396 people
- Sponsor
- Shire
Deafness
Word Learning in Deaf Children Using Eye-tracking and Behavioral Measures
Mutual exclusivity is a word learning constraint in which the learner assumes that a given word refers to only one category of objects.
- Trial name
- NCT05993832
- Testing
- input cue
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Boston University Charles River Campus
Autism, Cognition Disorder
The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism
This study will test whether donepezil (Aricept(Registered Trademark)), a drug that is approved by the Food and Drug Administration to treat Alzheimer's disease, can increase rapid eye movement (REM) sleep in children with autism…
- Trial name
- NCT00695136
- Testing
- Donepezil hydrochloride, Increase REM sleep percentage
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Mental Health (NIMH)
Autism, Attention Deficit Disorder With Hyperactivity
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
This study examined the cognitive and behavioral differences in children who have an autism spectrum disorder (ASD) with or without additional symptoms of ADHD.
- Trial name
- NCT00178503
- Testing
- Methylphenidate-extended release, Methylphenidate-immediate release
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory…
- Trial name
- NCT00776009
- Testing
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
- Where
- 8 sites in United States
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01244490
- Testing
- Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride
- Where
- 66 sites in United States, Austria and 11 more
- Volunteers
- 338 people
- Sponsor
- Shire
Autism Spectrum Disorder, Depression
Group Depression Treatment for Autistic Youth
Higher rates of depression are reported by autistic adolescents as compared to their non-autistic peers, which is problematic given adverse outcomes (e.g., negative self-esteem, lower academic performance) that are associated…
- Conditions
- Autism Spectrum Disorder, Depression, Suicidal Ideation, Self Esteem
- Trial name
- NCT05430022
- Testing
- Autism-adapted Group Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Vanderbilt University Medical Center
Attention Deficit Hyperactivity Disorder
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study
This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12…
- Trial name
- NCT03088267
- Testing
- amphetamine extended-release oral suspension, 2.5 mg/mL
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Tris Pharma, Inc.
Autism, Asperger's Syndrome
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
Autism spectrum disorders affect as many as 1 out of 150 children and are related to significant impairment in social, adaptive, and school functioning.
- Conditions
- Autism, Asperger's Syndrome, Generalized Anxiety Disorder, Social Phobia
- Trial name
- NCT01178385
- Testing
- Cognitive-behavioral therapy, Treatment as Usual
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Insomnia, Attention Deficit Hyperactivity Disorder
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
- Trial name
- NCT00857220
- Testing
- eszopiclone
- Where
- 89 sites in United States
- Volunteers
- 304 people
- Sponsor
- Sumitomo Pharma America, Inc.